- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Urine Test to Predict Recurrence of Bladder Cancer
A DNA methylation marker test performed on urine samples obtained from patients with non-muscle-invasive bladder cancer (NMIBC) has the ability to predict tumor recurrence with both high sensitivity and specificity.
A DNA methylation marker test performed on urine samples obtained from patients with non-muscle-invasive bladder cancer (NMIBC) has the ability to predict tumor recurrence with both high sensitivity and specificity.
The urine test, which measures three distinct DNA methylation markers, detected tumor recurrence with both high sensitivity and specificity (80% sensitivity and 97% specificity) in NMIBC patients.
While standard methods of monitoring which include cytology and cystoscopy were able to detect tumor recurrence in only 35 percent and 15 percent of these patients respectively, the new marker test performed well and predicted tumor recurrence in 80 percent of the patients who had a recurrence.The research
was published online April 1 in
, a journal of the American Association for Cancer Research.
Read the original report here:
Source: Forbes
Clinical Cancer Research
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Trastuzumab Deruxtecan Receives FDA Approval for HER2-Positive Solid Tumors
April 5th 2024FDA granted accelerated approval to trastuzumab deruxtecan-nxki for adult patients with unresectable or metastatic HER2-positive solid tumors who received prior systemic treatment and have no satisfactory alternative treatment options.
Read More
